ASCVD 10-Year Risk Calculator

How to Use This Calculator

1. Enter age (40-79), sex, race, cholesterol values, blood pressure, and risk factors.
2. 10-year ASCVD risk, risk category, and statin recommendation update instantly.
3. Use the Risk Enhancers tab to check if additional factors shift the treatment decision.
4. Professional tier adds statin intensity guidance and ESC SCORE2 comparison note.

Formula

Example

Frequently Asked Questions

• What is ASCVD risk and how is it calculated? ▼
  ASCVD stands for Atherosclerotic Cardiovascular Disease, encompassing coronary heart disease, stroke, and peripheral artery disease — the major clinical manifestations of atherosclerosis. The 10-year ASCVD risk is the estimated probability of experiencing a first atherosclerotic cardiovascular event (non-fatal myocardial infarction, coronary heart disease death, or fatal or non-fatal stroke) within the next 10 years. It is calculated using the ACC/AHA Pooled Cohort Equations, developed by Goff et al. and published in Circulation in 2013. The equations were derived from pooled data from multiple large longitudinal cohort studies (ARIC, CHS, CARDIA, Framingham Original, and Framingham Offspring) involving over 24,000 participants. Separate equations are provided for White men, White women, African American men, and African American women. Input variables include age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure treatment status, smoking status, and diabetes. The output is a continuous probability that can be categorized as low (< 5%), borderline (5-7.5%), intermediate (7.5-20%), or high (≥ 20%).
• What level of risk warrants statin therapy? ▼
  The ACC/AHA 2018 Cholesterol Guideline and 2019 Primary Prevention Guideline define risk-based thresholds for statin initiation in primary prevention (patients without established ASCVD). High risk: 10-year ASCVD ≥ 20% — high-intensity statin therapy is recommended, targeting ≥50% LDL-C reduction (atorvastatin 40-80 mg or rosuvastatin 20-40 mg). Intermediate risk: 7.5-20% — moderate-to-high intensity statin is recommended in most patients (atorvastatin 10-20 mg or rosuvastatin 5-10 mg achieving 30-50% LDL-C reduction). Borderline risk: 5-7.5% — statin therapy is reasonable to consider, particularly when risk enhancers are present (see below). Low risk: < 5% — lifestyle modification is the primary intervention; statin therapy is not routinely recommended. A crucial update in the 2018/2019 guidelines is that clinical judgment and shared decision-making are emphasized — a high ASCVD risk alone is not sufficient reason to start a statin if the patient does not want it, and the decision should involve discussion of expected absolute benefit, potential adverse effects, and patient preferences.
• Why is race included in the ASCVD calculator? ▼
  Race is included in the Pooled Cohort Equations because the derivation cohorts showed significantly different cardiovascular risk relationships across racial groups after controlling for other risk factors. African American men and women have higher rates of ASCVD events than White Americans at the same levels of traditional risk factors, likely reflecting unmeasured social determinants of health, access to care, chronic stress, hypertension severity, and biological differences in risk factor progression. Separate equations for African Americans were developed to avoid systematic underestimation of their ASCVD risk. However, the inclusion of race in the algorithm has been criticized on several grounds: race is a social construct rather than a biological category; separate race equations may perpetuate health disparities rather than address root causes; and the Pooled Cohort Equations only explicitly model African American and White populations, potentially providing less accurate estimates for Hispanic, Asian, Native American, and other populations. The AHA/ACC guidelines acknowledge these limitations and note that for non-Black, non-White populations, the White equations are used by default while acknowledging potential underestimation. Newer risk calculators like ESC SCORE2 are moving toward race-free, country-calibrated models.
• How does the calculator differ for women under 60? ▼
  Women under 60 face a well-documented challenge with ASCVD risk estimation: they typically have lower absolute 10-year risk than men of the same age, often falling in the "low" (< 5%) category, yet may harbor substantial lifetime risk. This happens because women's atherosclerotic events occur on average 7-10 years later than men's, so the 10-year window captures proportionally less of their total cardiovascular risk compared to men. The ACC/AHA guidelines address this by recommending consideration of lifetime ASCVD risk (estimated from age 50 to lifetime) for younger women, particularly those aged 40-59. Additionally, the 2019 Primary Prevention Guideline introduced female-specific risk enhancers that may shift clinical decision-making toward earlier statin therapy even when 10-year ASCVD is below 7.5%: history of premature menopause (before age 40), history of preeclampsia or eclampsia during pregnancy, history of gestational hypertension or diabetes, and autoimmune inflammatory conditions like systemic lupus erythematosus or rheumatoid arthritis, which accelerate atherosclerosis. Women with these conditions may benefit from statin therapy at lower 10-year risk thresholds than the standard guideline recommendations.
• What are "risk enhancers" and how do they change my risk? ▼
  Risk enhancers are clinical conditions and biomarkers that indicate higher cardiovascular risk than predicted by 10-year ASCVD risk alone, and their presence favors initiating or intensifying statin therapy in borderline or low-intermediate risk patients. They were introduced in the ACC/AHA 2018 Cholesterol Guidelines as a mechanism to individualize statin therapy decisions beyond the binary threshold approach. The ACC/AHA-recognized risk enhancers include: family history of premature ASCVD (first-degree male relative < 55 years, female < 65 years); chronic kidney disease (eGFR 15-59 mL/min/1.73m²); high-sensitivity C-reactive protein (hsCRP) ≥ 2.0 mg/L; elevated Lp(a) ≥ 50 mg/dL or ≥ 125 nmol/L; ApoB ≥ 130 mg/dL; low ankle-brachial index (< 0.9); metabolic syndrome; chronic inflammatory conditions (psoriasis, HIV, rheumatoid arthritis); premature menopause; and preeclampsia history. When a patient with borderline or low-intermediate ASCVD risk (5-20%) has one or more risk enhancers, the guidelines recommend discussing statin therapy. A coronary artery calcium (CAC) score can be used as a tiebreaker when the treatment decision remains uncertain: CAC = 0 supports deferring therapy, while CAC ≥ 100 strongly favors initiating a statin.

Related Calculators